Journal
JOURNAL OF CYSTIC FIBROSIS
Volume 22, Issue -, Pages S45-S49Publisher
ELSEVIER
DOI: 10.1016/j.jcf.2022.10.007
Keywords
CFTR; Cystic fibrosis; Theratypes; Genome editing
Categories
Ask authors/readers for more resources
Despite advances in CF treatment, there is still a need to bring potentially curative therapies to all individuals with CF. This review discusses the missing aspects in treating all CF individuals and explores holistic approaches to identify drug targets and therapeutic approaches to correct the gene in its genome.
Despite the major advances and successes in finding and establishing new treatments that tackle the basic defect in Cystic Fibrosis (CF), there is still an unmet need to bring these potentially curative therapies to all individuals with CF. Here, we review aspects of what is still missing to treat all individuals with CF by such approaches. On the one hand, we discuss novel holistic (high-throughput) approaches to elucidate mechanistic defects caused by distinct classes of mutations to identify novel drug targets. On the other hand, we examine therapeutic approaches to correct the gene in its own environment, i.e., in the genome. (C) 2022 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available